Reuters: Regulatory News: Bayer says eye drug meets goal in diabetic macular edema trials

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Bayer says eye drug meets goal in diabetic macular edema trials Aug 6th 2013, 06:46 FRANKFURT | Tue Aug 6, 2013 2:46am EDT FRANKFURT Aug 6 (Reuters) - Bayer said on Tuesday that two late-stage studies testing its drug VEGF Trap-Eye against diabetic macular edema (DME) met their primary goals. Bayer co-develops the eye drug, also known as Eylea, with Regeneron. Bayer said that Regeneron now expects to submit an application for U.S. marketing approval for the treatment of DME in 2013, about a year earlier that previously planned.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions